Aroa Biosurgery Ltd (ASX: ARX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Aroa Biosurgery Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $243.15 million
P/E Ratio 23.47
Dividend Yield 0.00%
Shares Outstanding 344.90 million
Earnings per share -0.020
Dividend per share N/A
Year To Date Return -15.06%
Earnings Yield 4.26%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Aroa Biosurgery Ltd (ASX: ARX)
    Latest News

    A man wearing glasses and a white t-shirt pumps his fists in the air looking excited and happy about the rising OBX share price
    Small Cap Shares

    2 small cap ASX stocks with big price targets

    Brokers have put big price targets on these small caps this month.

    Read more »

    A young man wearing a black and white striped t-shirt looks surprised.
    Small Cap Shares

    Experts name 2 small cap ASX stocks to buy for big returns

    Analysts have good things to say about these high risk-high reward investment options.

    Read more »

    Rising share price chart.
    Small Cap Shares

    3 small cap ASX stocks that could rise 40% to 100%+

    Brokers believes these small caps could be worth a closer look.

    Read more »

    a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
    Healthcare Shares

    Bell Potter names the best ASX healthcare stocks to buy in FY25

    These stocks could bring your portfolio to life in the new financial year.

    Read more »

    A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
    Small Cap Shares

    Guess which small cap ASX stock could rise 50% in a 'transformational year'

    This small cap has been tipped to rise materially from current levels. But why?

    Read more »

    Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
    Healthcare Shares

    3 ASX healthcare shares outperforming on quarterly updates

    These stocks are charging ahead on an otherwise lacklustre trading day.

    Read more »

    A worried man holds his head and look at his computer.
    Share Fallers

    Why 29Metals, Aroa Biosurgery, Mader, and Netwealth shares are falling

    Investors are selling down these shares on Tuesday. But why?

    Read more »

    A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
    Share Fallers

    Why Aroa Biosurgery, Bank of Queensland, Champion Iron, and Terracom shares are falling

    These ASX shares are ending the month deep in the red.

    Read more »

    a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
    Healthcare Shares

    Morgans says these small cap ASX healthcare shares are buys with 50% upside

    Looking for big returns? Then you might want to look at the small side of the market.

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Broker Notes

    Buy these 2 ASX health-tech shares that are ready to rocket: Wilson

    Consumers still want to stay healthy even through tough economic times.

    Read more »

    Arrows pointing upwards with a man pointing his finger at one.
    52-Week Highs

    4 ASX All Ordinaries shares hitting new 52-week highs today

    Do you know the coal and healthcare shares trading at 12-month highs?

    Read more »

    a person stands on top of a mountain with hands raised above their head gazing on an amazing sunrise over the landscape and above the clouds.
    52-Week Highs

    5 ASX All Ords shares cracking new 52-week highs on Tuesday

    Are your investments trading at their highest point in more than 12 months today?

    Read more »

    Frequently Asked Questions

    No, Aroa Biosurgery does not pay shareholder dividends at this time.

    Aroa Biosurgery Ltd listed on the ASX on 24 July 2020.

    ARX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Aroa Biosurgery Ltd

    Aroa Biosurgery Ltd (ASX:  ARX) is a New Zealand-based biomedical company specialising in  soft tissue regeneration. It develops, manufactures, and distributes medical and surgical products to improve the healing of complex wounds and soft tissue reconstruction.

    The company's principal market is the United States where it markets four key products targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.

    Its first wound-healing product Endoform was approved by the US Food & Drug Administration (FDA) in 2013. Aroa's first commercial surgical product, a reinforced bioscaffold developed in collaboration with US company Tela Bio Inc., was approved by the FDA in 2014.

     

    ARX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    29 Nov 2024 $0.71 $-0.01 -1.41% 582,508 $0.71 $0.71 $0.65
    28 Nov 2024 $0.71 $0.02 2.90% 376,568 $0.71 $0.75 $0.71
    27 Nov 2024 $0.69 $0.02 2.99% 1,166,495 $0.67 $0.71 $0.67
    26 Nov 2024 $0.67 $0.02 3.08% 1,195,455 $0.66 $0.68 $0.65
    25 Nov 2024 $0.65 $-0.01 -1.53% 672,519 $0.66 $0.67 $0.65
    22 Nov 2024 $0.66 $0.01 1.54% 340,780 $0.65 $0.66 $0.65
    21 Nov 2024 $0.65 $0.02 3.15% 145,776 $0.65 $0.65 $0.63
    20 Nov 2024 $0.64 $-0.02 -3.08% 1,197,838 $0.65 $0.65 $0.63
    19 Nov 2024 $0.65 $0.02 3.17% 516,401 $0.62 $0.65 $0.62
    18 Nov 2024 $0.63 $0.00 0.00% 106,128 $0.66 $0.66 $0.63
    15 Nov 2024 $0.63 $0.01 1.60% 73,738 $0.63 $0.63 $0.61
    14 Nov 2024 $0.63 $-0.03 -4.62% 171,063 $0.66 $0.66 $0.62
    13 Nov 2024 $0.65 $-0.03 -4.44% 226,589 $0.68 $0.68 $0.65
    12 Nov 2024 $0.68 $0.03 4.62% 460,766 $0.65 $0.69 $0.65
    11 Nov 2024 $0.65 $0.04 6.56% 436,885 $0.61 $0.66 $0.60
    08 Nov 2024 $0.61 $0.01 1.67% 49,466 $0.61 $0.61 $0.60
    07 Nov 2024 $0.60 $0.03 5.26% 60,237 $0.58 $0.60 $0.54
    06 Nov 2024 $0.57 $0.01 1.79% 23,888 $0.58 $0.59 $0.57
    05 Nov 2024 $0.56 $-0.01 -1.75% 880,869 $0.57 $0.57 $0.55
    04 Nov 2024 $0.57 $-0.03 -5.00% 68,247 $0.59 $0.61 $0.57
    01 Nov 2024 $0.60 $-0.02 -3.25% 91,656 $0.62 $0.62 $0.60

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    30 Sep 2024 Catherine Mohr Buy 436,364 $163,453
    On-market trade.
    22 Aug 2024 Darla Hutton Issued 140,110 $140,110
    Issue of securities. NZD
    22 Aug 2024 Brian Ward Issued 961,255 $422,952
    Issue of securities. 961,255 Performance Rights
    27 Mar 2024 Steven (Steve) Engle Exercise 633,225 $61,992
    Exercise of options. NZ$
    27 Mar 2024 Steven (Steve) Engle Issued 633,225 $61,992
    Exercise of options. NZ$
    16 Feb 2024 Philip McCaw Buy 326,000 $187,450
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr John Flower Diddams Non-Executive Director Nov 2019
    Mr Diddams has over forty years' experience as a CFO, CEO and director of both private and publicly listed companies. John is currently a non-executive director of Surf Lakes Holdings Limited and DIT AgTech Limited. John has knowledge and experience in the practical application of ASX Listing Rules, Australian corporations law, international accounting standards and corporate governance principles. He heads a CPA firm providing corporate advisory services to SME and mid-cap companies and has managed the listing process, secondary capital raisings and ASX listings in a number of industry sectors, including oil and gas, food and retail, telecommunications, adventure tourism, biotechnology, and the dental and medical sectors.
    Mr Philip John McCaw Non-Executive Director Mar 2008
    Mr McCaw is the Founding Partner of Movac, one of New Zealand's venture capital funds. He is currently the Executive Chair and CEO of Author-IT Software Corporation, a software company that delivers component authoring solutions, enabled by AI, for the largest global pharmaceutical companies. He was also the Chair of the 2023 New Zealand Government's Startup Advisors' Council, established to help identify and address the opportunities and challenges facing high growth start-up businesses. Phil has over 20 years' experience investing into New Zealand technology companies and helping to guide their growth. He was an early investor in Trade Me, New Zealand's leading on-line trading community, which was sold to Fairfax in 2006. Phil was also an early investor into PowerByProxi, a wireless power technology spin-out from Auckland University, which was sold to Apple in 2018. Outside of Movac, Phil remains an angel investor and maintains a personal angel investment portfolio. He is advocate for the development of the entrepreneurial and early-stage investment eco-system in New Zealand and was the past Chair of the Angel Association of New Zealand. Prior to starting Movac, Phil spent 10 years with Deloitte Consulting working in New Zealand and the US.
    Mr James (Jim) Neil McLean Non-Executive ChairmanNon-Executive Director Aug 2011
    Mr McLean has over 25 years' experience serving as chair, director, or an executive of research and technology businesses for both commercial and New Zealand Government organisations. In addition to AROA, Jim is also Chair of Prevar Limited. He was Chair of the New Zealand Institute of Plant & Food Research and Chair of its predecessor HortResearch, as well as several private businesses and start-up companies. He served on the board of the then Foundation for Research, Science, and Technology including five years as Deputy Chair. Jim was an executive and director of Genesis Research & Development Corporation Limited during its early stages through to public listing. Before specialising in science and technology businesses, Jim held management positions with an international manufacturing business and spent thirteen years as a partner at chartered accountants, EY. His time at EY was focused on business strategy and included two years' secondment to EY's Washington DC office.
    Mr John Richard Pinion II Non-Executive Director Feb 2015
    Mr Pinion is a resident of the US. He has over 30 years of global experience leading biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe and the Americas. His expertise and leadership spans engineering, quality, manufacturing and translational sciences. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. He provides leadership for Ultragenyx's translational sciences functions which includes Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance and CMC Analytical QC. As a member of Ultragenyx's executive leadership team reporting directly to the CEO, he also contributes to ongoing business development, clinical development, commercial and strategic planning activities. John is also an advisory board member for Celestial Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialisation of next-generation novel and ground breaking mRNA vaccines and therapeutics for the treatment and prevention of infectious diseases, rare diseases and cancers. John has previously held operational and senior leadership roles in Genentech (subsequently Roche post Genentech acquisition, as Senior Vice President and Global Head of Quality and Compliance for Pharma Technical Operations) and Baxter International's Renal, Bioscience, Parenterals and Device divisions. He is Chair of the Risk Committee.
    Mr Brian Roderick Ward Chief Executive OfficerManaging Director Sep 2007
    Mr Ward has held corporate roles in life sciences and health care companies for more than 25 years. He has management experience in life science companies spanning clinical, technical, sales, marketing, corporate development and strategy having worked for multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, and has sat on government and industry expert panels.
    Dr Catherine Mohr Non-Executive Director Nov 2022
    Dr Mohr has over 30 years' experience across fields, including engineering, healthcare, alternative energy, aerospace and global entrepreneurship. Her expertise spans many areas related to AROA's next stage of growth, including medtech product research and development, FDA approvals, product commercialisation and surgery technology innovation. She has been President of the Intuitive Foundation since 2018. Prior to leading the Foundation, Catherine held senior roles at Intuitive Surgical, including Vice President of Strategy and Director of Medical Research. Intuitive Surgical is a pioneer in the robotic-assisted surgery field and developed the da Vinci surgical robotic system which is used in millions of surgical procedures across the globe every year. Catherine is also on the board of directors for FINCA International and cofounded VeriSure, where she invented the LapCap, the first of a new category of laparoscopic surgery enabling products. She is member of the Risk Committee.
    Ms Darla Hutton Non-Executive Director Mar 2024
    Ms Hutton has more than 25 years of medical technology experience, including global leadership expertise in commercial strategy, operations, sales, marketing, healthcare analytics, lean and enterprise consulting. Darla is currently Vice President, Asia Commercial Operations and Marketing at Intuitive, pioneers in the field of robotic-assisted surgery and maker of the da Vinci surgical and ION diagnostic robot systems. Throughout her tenure at Intuitive, Darla has held commercial roles of increasing responsibility including Regional Sales Director, Vice President of Corporate Accounts-US, and Vice President Marketing, Market Access & Custom Hospital Analytics. In these roles, she has contributed to the expansion of Intuitive's commercial operations capabilities and global offerings. In addition, Darla has served as a member of Intuitive's Inclusion and Diversity Executive Council. Prior to Intuitive, Darla held commercial positions at other medical technology, pharmaceutical, and biotech companies, including Boston Scientific and GlaxoSmithKline, and spent her early professional career in the cardiac-thoracic nursing field. She is member of risk committee.
    Ms Tracy Weimar Joint Company Secretary Jul 2020
    -
    Mr James Blair Agnew Chief Financial OfficerJoint Company Secretary
    -
    James Blair Agnew Chief Financial OfficerJoint Company Secretary
    -
    Barnaby May Chief Scientific Officer
    -
    Rod Stanley Chief Technology Officer
    -
    Tracy Weimar Joint Company Secretary
    -
    Yasmin Winchester Vice President Quality Regulatory and Sustainability
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 48,251,491 14.01%
    Mr Brian Ward & Mrs Tracey Ward <Arawai No 2 A/C> 33,125,800 9.62%
    HSBC Custody Nominees (Australia) Limited 32,670,040 9.49%
    Citicorp Nominees Pty Limited 32,037,722 9.30%
    Phil Mccaw <Mcsyth Capital Invest A/C> 19,597,251 5.69%
    Richard Abbott <Jester 002 Investment A/C> 13,043,020 3.78%
    BNP Paribas Noms (Nz) Ltd 10,520,679 3.05%
    Aspire Nz Seed Fund Ltd 10,421,614 3.02%
    National Nominees Limited 8,010,852 2.32%
    K One W One (No 3) Ltd 5,882,550 1.70%
    Custodial Services Limited <Beneficiaries Holding A/C> 4,532,679 1.31%
    Sharon Bryant <Ot Investment A/C> 4,372,267 1.27%
    HSBC Custody Nominees (Australia) Limited A/C 2 4,138,307 1.20%
    Mr John Anthony Dell 3,508,864 1.01%
    Bnp Paribas Noms Pty Ltd 3,387,642 0.98%
    UBS Nominees Pty Ltd 3,336,270 0.96%
    Barnaby May 3,272,775 0.95%
    Christopher David Astley Milne 3,213,022 0.93%
    K One W One Ltd 3,041,226 0.88%
    James Mclean 2,827,108 0.82%

    Profile

    since

    Note